Aditxt, Inc.
ADTX · XXXXCIK 1726711fmd_1W1GSYBQ178YFX7MDB29XYRA7BManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Mar 31, 2026, 30 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 0 | 1 | 1 | 0 | 0 |
| Property operating expenses | 0 | 0 | – | – | – | – | – |
| Cost of revenue | – | – | 0 | 1 | 1 | 1 | 0 |
| Gross profit | – | – | 0 | 0 | (0) | (0) | 0 |
| Research and development | 0 | 1 | 5 | 7 | 7 | 11 | 3 |
| Selling, general and administrative | 0 | 0 | 0 | 18 | 19 | 16 | 16 |
| Total operating expenses | 6 | 9 | 42 | 26 | 26 | 27 | 20 |
| Operating income | (6) | (9) | (42) | (25) | (26) | (28) | (20) |
| Interest expense | – | 0 | 0 | 0 | 4 | 4 | 1 |
| Interest and investment income | – | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | 0 | (0) | (4) | (2) | (6) | (7) | (23) |
| Income before taxes | – | (9) | (46) | (28) | (32) | (35) | (43) |
| Net income | (6) | (9) | (46) | (28) | (33) | (40) | (43) |
| Net income to common shareholders | – | – | (46) | (28) | (33) | – | – |